.webp){kind=logo}
GET UP TO 25% BONUS STOCK BY
Invest NowWhy we founded RegenMed.
What we have learned about the market, and ourselves.
How we think about shareholder value.
Not only a powerful business model, but a compelling mission.
“Nothing Is More Powerful Than An Idea Whose Time Has Come." – Victor Hugo
A Zero To One company recognizes early on the implications of powerful macro trends.
It is founded on theses which transform major markets, and create new ones.
It possesses the leadership necessary to capture the benefits of its market disruption and creation.
It richly rewards early stage investors.
“A plan without action is a daydream; action without a plan is a nightmare." — Japanese proverb
Healthcare is broken because healthcare data is broken.
It is not corporations, but physicians and patients which are the most powerful sources of healthcare data.
Modern technology and processes focused on physicians and patients will enable a far more efficient, equitable and lower cost approach to healthcare data.
RegenMed has the leadership and market traction to translate these transformational theses into shareholder value.
“Nothing succeeds like success.”
Patented cloud-based platform capturing, aggregating and correlating primary clinical and outcomes data from everyday clinical interventions.
Generation of unbiased coherent datasets which are clinically and statistically significant, proprietary, and regulatorily-compliant.
Multiple value propositions for payers, product manufacturers, providers, research centers and other healthcare constituencies.
Fast growing recurring revenues from an international, diverse client base.
Strong inherent network effects.
"The best way to predict the future is to create it." – Peter Drucker
Recursive AI-learning model supporting natural language databases for an increasing number of pathologies and treatment protocols.
Blockchain and tokenization to support enhanced security of, and incentives to provide, protected health information.
Licensing of proprietary databases and patented healthcare data platform to payers, researchers, providers.
Continued geographic expansion.
Explore liquidity events, including regional joint ventures, direct listing, health record token monetization.
We partnered with RegenMed over a year ago to collect real-world data by using RegenMed’s Circles Program in order to collect data that can be used to provide evidence, more than trends only.
Our goal is ultimately to have clear cut evidence what optimal preparation methods and protocols are to facilitate physicians in optimizing their treatment strategies, using a variety of highly efficient and reproducible protocols.
The platform has accommodated our highly specific research objectives, customer engagement and feedback has been overwhelmingly positive, and we have already generated valuable, statistically significant data for up to 1 year, clearly leading us to further refinement of our protocols.
Peter Everts, PhD, FRSM
Preserving joints instead of replacing them! The possibilities for joint-preserving treatment options are already impressive today. The experience of the practitioner plays an important role. Personally, it is of particular importance to me to objectively document treatment options and their successes. RegenMed provides an excellent platform for this.
Dr. Marcus Klingenberg | BetaKlinik
The Circles platform is very user friendly. The system is completely automated so that the reminders come to the patients, who fill in the data, which then comes to us directly for our analysis. We are able to establish a very good percentage of participation amongst our patients.
I want objective numbers I can share with patients. It is also important for me to be able to share my outcomes with my colleagues. Finally, I want to collect these categories of data since we are in a field facing increased regulatory oversight.
Grant Pagdin, M.D. | Pagdin Health
The field of regenerative medicine remains growing, both in size and in need for evidence-based standards. ROSM has long been a pioneer of non-surgical treatment options, and that leadership will now extend to the generation and dissemination of real-world evidence across a growing number of protocols, products, and patient populations.
RegenMed shared our strategic vision, and with its turnkey platforms and deep regenerative medicine experience, was the natural partner to help us design and expand this broad initiative.
Imran Siddiqui, M.D., Director of Clinical Operations | ROSM
Breakthrough Regenerative Orthopedics is proud to partner with RegenMed to collect real world evidence on treating SI dysfunction and ligamentous laxity. RegenMed has become our go-to partner for clinical data collection based on their commitment to user-friendly, customer-focused data collection solutions for busy clinicians like ourselves.
Timothy Mazzola, M.D. | Breakthrough Regenerative Orthopedics
I am excited to be working with RegenMed in executing the RWE Program. This will help to expand Summus’ clinical and scientific correlations and reach a broader team of providers to collect valuable data.
Dr. Phil Harrington, Internationally Recognized Expert in Laser Therapies
I consider it extremely important to maintain data in the practice of medicine, especially in the application of orthobiologic therapies. It is the best way to understand what truly works, to what extent, for how long, and what can be improved. RegenMed is a valuable ally in our effort to collect reliable and objective medical data.
Dimitrios Tsoukas, M.D., M.Sc.; Founder, IARMES
The testimonials presented are the opinions of the individuals providing them. They may not represent the experience of all clients or investors and are not a guarantee of future performance or success. No compensation was provided for these testimonials unless explicitly stated
RegenMed is offering the following Bonus Shares in connection with this Reg CF Offering. One must submit a single investment in the same offering that meets the minimum Bonus Share requirement. Bonus shares will not be granted if an investor submits multiple investments which, when combined, meet the Bonus Share requirement. All Bonus Shares are issued when the offering is completed. See the Company’s Form C for further details on Bonus Shares.
Regulation CF allows investors to invest in startups and early-growth companies. This is different from helping a company raise money on Kickstarter; with Regulation CF Offerings, you aren’t buying products or merchandise - you are buying a piece of a company and helping it grow.
Accredited investors can invest as much as they want. But if you are NOT an accredited investor, your investment limit depends on either your annual income or net worth, whichever is greater. If the number is less than $124,000, you can only invest 5% of it. If both are greater than $124,000 then your investment limit is 10%.
To calculate your net worth, just add up all of your assets and subtract all of your liabilities (excluding the value of the person’s primary residence). The resulting sum is your net worth.
We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.
Individuals over 18 years of age can invest.
There will always be some risk involved when investing in a startup or small business. And the earlier you get in the more risk that is usually present. If a young company goes out of business, your ownership interest could lose all value. You may have limited voting power to direct the company due to dilution over time. You may also have to wait about five to seven years (if ever) for an exit via acquisition, IPO, etc. Because early-stage companies are still in the process of perfecting their products, services, and business model, nothing is guaranteed. That’s why startups should only be part of a more balanced, overall investment portfolio.
The Common Stock (the "Shares") of Westbound and Down (the "Company") are not publicly-traded. As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically look to receive a return on your investment under the following scenarios: The Company gets acquired by another company. The Company goes public (makes an initial public offering). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on an exchange. These are both considered long-term exits, taking approximately 5-10 years (and often longer) to see the possibility for an exit. It can sometimes take years to build companies. Sometimes there will not be any return, as a result of business failure.
Shares sold via Regulation Crowdfunding offerings have a one-year lockup period before those shares can be sold under certain conditions. Exceptions to limitation on selling shares during the one-year lockup period:
In the event of death, divorce, or similar circumstance, shares can be transferred to:
If a company does not reach their minimum funding target, all funds will be returned to the investors after the close of the offering.
All available disclosure information can be found on the offering pages for our Regulation Crowdfunding offering.
You can cancel your investment at any time, for any reason, until 48 hours prior to a closing occurring. If you’ve already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email: info@dealmakersecurities.com
At a minimum, the company will be filing with the SEC and posting on its website an annual report, along with certified financial statements. Those should be available 120 days after the fiscal year end. If the company meets a reporting exception, or eventually has to file more reported information to the SEC, the reporting described above may end. If these reports end, you may not continually have current financial information about the company.
Once an offering ends, the company may continue its relationship with DealMaker Securities for additional offerings in the future. DealMaker Securities’ affiliates may also provide ongoing services to the company. There is no guarantee any services will continue after the offering ends.
.png)
